TY - JOUR
T1 - Effect of protease inhibitor on primary glomerulonephritis and the mechanism of the effect
AU - Onbe, Tsuneto
AU - Makino, Hirofumi
AU - Haramoto, Toshinori
AU - Ogura, Toshirou
AU - Kumagai, Isao
AU - Murakami, Kazuharu
AU - Fukushima, Masaki
AU - Ota, Zensuke
PY - 1991/1
Y1 - 1991/1
N2 - Effect of serine protease inhibitor Camostat Mesilate (Foipan®) on primary glomerulonephritis and it's mechanism were evaluated. Forty-two patients having primary glomerulonephritis (13 cases of IgA nephropathy, 11 cases of membranous nephropathy and others), aged 18 to 81 years were selected for this study. At the start of our study, twenty-one patients had received other drugs (13 cases of dipyridamole and 13 cases of prednisolone). A control period of four weeks was established to confirm that the levels of proteinuria and renal functions were stable. Patients were orally administered with 600 mg of Camostat Mesilate per day for four weeks. Effect of Camostat Mesilate was judged by urinary protein excretion, hematuria, serum total protein, albumin, Ccr, creatinine and BUN. In order to reveal the mechanism of the effect laboratory data such as granulocyte elastase, CH50, C3, C4, fibrinogen, platelate factor 4, β3-thromboglobulin, thromboxane B2 and prostaglandin F1α were evaluated before and after the treatment. Parameters were analyzed by using paired t-test. Mean (±SEM) urinary protein excretion reduced from 4. 31 ±0.91 to 2. 80±0.43g/day (p<0.05), and score of hematuria decreased from 1.8±0.16 to 1.5 + 0.15. A significant decrease in urinary protein excretion was seen in membranous nephropathy and a significant decrease in hematuria was seen in IgA nephropathy. In combination therapy (dipyridamole, prednisolone) urinary protein excretion markedly decreased (p<10.05) and in Camostat Mesilate therapy score of hematuria markedly decreased (p<0.05). Camostat Mesilate had no effects on renal function assessed by Ccr, creatinine and BUN. During observation period there were no significant changes in serum complement titers, prostanoids, granulocyte elastase and other parameters. From our present study, Camostat Mesilate had beneficial effects on primary glomerulonephritis, although the exact mechanism of these effects of the drug could not be elucidated. We consider that proteinase inhibitors may be beneficial for the treatment of primary glomerulonephritis.
AB - Effect of serine protease inhibitor Camostat Mesilate (Foipan®) on primary glomerulonephritis and it's mechanism were evaluated. Forty-two patients having primary glomerulonephritis (13 cases of IgA nephropathy, 11 cases of membranous nephropathy and others), aged 18 to 81 years were selected for this study. At the start of our study, twenty-one patients had received other drugs (13 cases of dipyridamole and 13 cases of prednisolone). A control period of four weeks was established to confirm that the levels of proteinuria and renal functions were stable. Patients were orally administered with 600 mg of Camostat Mesilate per day for four weeks. Effect of Camostat Mesilate was judged by urinary protein excretion, hematuria, serum total protein, albumin, Ccr, creatinine and BUN. In order to reveal the mechanism of the effect laboratory data such as granulocyte elastase, CH50, C3, C4, fibrinogen, platelate factor 4, β3-thromboglobulin, thromboxane B2 and prostaglandin F1α were evaluated before and after the treatment. Parameters were analyzed by using paired t-test. Mean (±SEM) urinary protein excretion reduced from 4. 31 ±0.91 to 2. 80±0.43g/day (p<0.05), and score of hematuria decreased from 1.8±0.16 to 1.5 + 0.15. A significant decrease in urinary protein excretion was seen in membranous nephropathy and a significant decrease in hematuria was seen in IgA nephropathy. In combination therapy (dipyridamole, prednisolone) urinary protein excretion markedly decreased (p<10.05) and in Camostat Mesilate therapy score of hematuria markedly decreased (p<0.05). Camostat Mesilate had no effects on renal function assessed by Ccr, creatinine and BUN. During observation period there were no significant changes in serum complement titers, prostanoids, granulocyte elastase and other parameters. From our present study, Camostat Mesilate had beneficial effects on primary glomerulonephritis, although the exact mechanism of these effects of the drug could not be elucidated. We consider that proteinase inhibitors may be beneficial for the treatment of primary glomerulonephritis.
KW - IgA nephropathy
KW - camostat mesilate
KW - glomerulonephritis
KW - nephrotic syndrome
KW - protease inhibitor
UR - http://www.scopus.com/inward/record.url?scp=0025947762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025947762&partnerID=8YFLogxK
U2 - 10.14842/jpnjnephrol1959.33.753
DO - 10.14842/jpnjnephrol1959.33.753
M3 - Article
C2 - 1770635
AN - SCOPUS:0025947762
VL - 33
SP - 753
EP - 759
JO - Japanese Journal of Nephrology
JF - Japanese Journal of Nephrology
SN - 0385-2385
IS - 8
ER -